All the Active Ingredient Drugs
Insulin-Like Growth Factor-1 Receptor Antagonist. Teprotumumab 500 mg/vial. VIAL 1X 500 mg, powder for concen. for sol. for inf.
Assess pts. for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with this drug. Ensure pts. with hyperglycemia or pre-existing diabetes are under appropriate glycemic ctrol. before and while receiving this drug.
Assess pts.’ hearing before, during, and after tmt. with this drug and consider the benefit-risk of tmt.
The recommended dose is an IV infusion of 10 mg/kg for the initial dose followed by an IV infusion of 20 mg/kg every three weeks for 7 additional infusions.
Tmt. of moderate to severe Thyroid Eye Disease regardless of activity and duration
C/I: Hypersens
